


**Product Name** : MK-8353  
**Cat. No.** : PC-62595  
**CAS No.** : 1184173-73-6  
**Molecular Formula** : C<sub>37</sub>H<sub>41</sub>N<sub>9</sub>O<sub>3</sub>S  
**Molecular Weight** : 691.855  
**Target** : ERK  
**Solubility** : DMSO: 125 mg/mL (180 mM)



### Biological Activity

MK-8353 (SCH-900353) is a highly potent, orally bioavailable, dual-specificity **ERK1/2** inhibitor with IC<sub>50</sub> of 23.0/8.8 nM, respectively.

MK-8353 inhibits nonactivated ERK2 with IC<sub>50</sub> of 0.5 nM, demonstrates excellent kinase selectivity over a 227-human kinase panel.

MK-8353 decreases pERK1, pERK2, and ribosomal S6 kinase (pRSK) proteins, with complete suppression of pERK1 and pERK2 observed at 30 nM in A2058 cells.

MK-8353 inhibits the in vitro proliferation of a panel of BRAFV600-mutant and RAS-mutant cancer cell lines.

MK-8353 exhibits in vivo antitumor activity against BRAFV600 mutant Colo-205 colon cancer model and the BRAFV600 mutant SK-MEL-28 melanoma model.

### References

Moschos SJ, et al. *JCI Insight*. 2018 Feb 22;3(4). pii: 92352.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com